Advice
following a full submission:
lurasidone (Latuda®) is accepted for restricted use within NHS Scotland.
Indication under review: For the treatment of schizophrenia in adults aged 18 years and over.
SMC Restriction: as an alternative treatment option in patients in whom it is important to avoid weight gain and metabolic adverse effects.
Lurasidone demonstrated benefit over placebo in mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score after six weeks of treatment and was non-inferior to another second generation antipsychotic medicine for time to relapse over 12 months.
Download detailed advice197KB (PDF)
Medicine details
- Medicine name:
- lurasidone (Latuda)
- SMC ID:
- 994/14
- Indication:
- For the treatment of schizophrenia in adults aged 18 years and over.
- Pharmaceutical company
- Sunovion
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 October 2014